Clover Health Investments(CLOV) - 2024 Q3 - Quarterly Report

Business Operations - As of September 30, 2024, Clover Health operates Medicare Advantage plans in five states and 200 counties, serving 81,110 members[150]. - The company launched Counterpart Health, a SaaS solution aimed at extending the benefits of its technology to Medicare Advantage payors and providers, with low startup costs and high-margin business opportunities[154]. - The company exited the ACO REACH program effective January 1, 2024, after determining it was in its best interest to do so[155]. Financial Performance - Premiums earned, gross for 2024 totaled $1,014,502,000, with a PMPM of$1,409, compared to $933,040,000 and a PMPM of$1,252 in 2023[159]. - Adjusted EBITDA for 2024 is $19,263,000, a significant increase from$2,723,000 in 2023, reflecting improved operational efficiency[159]. - Total revenues increased by $24.9 million, or 8.2$330.986 million for the three months ended September 30, 2024, compared to the same period in 2023[180]. - Net loss from continuing operations improved by $24.8 million, or 73.9$(8.8) million for the three months ended September 30, 2024, compared to $(33.6) million for the same period in 2023[179]. Claims and Expenses - Clover Health's net medical claims incurred for 2024 were$251,643,000, with a PMPM of $1,040, compared to$236,533,000 and a PMPM of $966 in 2023[159]. - The medical care ratio, gross for 2024 is reported at 78.1$14.0 million, or 6%, to $249.8 million for the three months ended September 30, 2024, compared to the same period in 2023[183]. Income and Cost Management - Other income rose by$3.6 million, or 75%, to $8.4 million for the three months ended September 30, 2024, attributed to a higher interest rate environment[182]. - Salaries and benefits decreased by$5.6 million, or 9%, to $55.0 million for the three months ended September 30, 2024, primarily due to lower share-based compensation costs[184]. - General and administrative expenses decreased by$5.8 million, or 14%, to $35.2 million for the three months ended September 30, 2024, driven by a reduction in professional fees[185]. Cash Flow and Investments - Net cash provided by operating activities from continuing operations was$129.5 million for the nine months ended September 30, 2024, reflecting a net loss of $20.9 million[207]. - Net cash provided by investing activities was$2.0 million for the nine months ended September 30, 2024, primarily due to $156.6 million from the sale and maturity of investment securities[209]. - Total restricted and unrestricted cash, cash equivalents, and investments for all entities were$531.4 million at September 30, 2024, compared to $417.3 million at December 31, 2023[199]. Risk Management - The company is primarily exposed to interest rate risk associated with investments in fixed maturity instruments[222]. - Credit risk is managed by investing in high-quality securities and diversifying holdings[223]. - The company does not have material exposure to commodity risk[222]. Accounting and Financial Measures - Clover Health utilizes non-GAAP measures such as Adjusted EBITDA and Adjusted SG&A to assess performance and future prospects[220]. - Non-GAAP financial measures should be read in conjunction with GAAP financial statements[220]. - Recent accounting pronouncements and their potential impact are discussed in the condensed consolidated financial statements[218].